Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Humanized C3 Mouse: A Novel Accelerated Model of C3 Glomerulopathy

ABSTRACT: Humanized C3 Mouse: A Novel Accelerated Model of C3 Glomerulopathy

PROVIDER: PRJNA633816 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR11811800.fastq.gz	Fastqsanger.gz
	SRR11811801.fastq.gz	Fastqsanger.gz
	SRR11811802.fastq.gz	Fastqsanger.gz
	SRR11811775.fastq.gz	Fastqsanger.gz
	SRR11811776.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 27

Similar Datasets

Humanized C3 Mouse: A Novel Accelerated Model of C3 Glomerulopathy

Project description:We developed a novel, rapidly-progressing, severe murine model of C3G by replacing the mouse C3 gene with the human C3 homologue using Velocigene® technology. We conducted functional, histological, molecular and pharmacologic assays to characterize the presentation of renal disease and useful pharmacologic interventions in the humanized C3 (C3hu/hu) mice.

2020-05-20 | GSE150838 | GEO

Humanized C3 Mouse: A Novel Accelerated Model of C3 Glomerulopathy.

Project description:BackgroundC3 glomerulopathy (C3G) is characterized by the alternative-pathway (AP) hyperactivation induced by nephritic factors or complement gene mutations. Mice deficient in complement factor H (CFH) are a classic C3G model, with kidney disease that requires several months to progress to renal failure. Novel C3G models can further contribute to understanding the mechanism behind this disease and developing therapeutic approaches.MethodsA novel, rapidly progressing, severe, murine model of C3G was developed by replacing the mouse C3 gene with the human C3 homolog using VelociGene technology. Functional, histologic, molecular, and pharmacologic assays characterize the presentation of renal disease and enable useful pharmacologic interventions in the humanized C3 (C3hu/hu) mice.ResultsThe C3hu/hu mice exhibit increased morbidity early in life and die by about 5-6 months of age. The C3hu/hu mice display elevated biomarkers of kidney dysfunction, glomerulosclerosis, C3/C5b-9 deposition, and reduced circulating C3 compared with wild-type mice. Administration of a C5-blocking mAb improved survival rate and offered functional and histopathologic benefits. Blockade of AP activation by anti-C3b or CFB mAbs also extended survival and preserved kidney function.ConclusionsThe C3hu/hu mice are a useful model for C3G because they share many pathologic features consistent with the human disease. The C3G phenotype in C3hu/hu mice may originate from a dysregulated interaction of human C3 protein with multiple mouse complement proteins, leading to unregulated C3 activation via AP. The accelerated disease course in C3hu/hu mice may further enable preclinical studies to assess and validate new therapeutics for C3G.

| S-EPMC7894673 | biostudies-literature

C3 Glomerulopathy: Novel Treatment Paradigms.

Project description:C3 glomerulopathy (C3G) is diagnosed by kidney biopsy, with immunofluorescence showing isolated or dominant C3 staining, indicating hyperactivity of the alternative complement pathway as the key driver of glomerular injury. Therefore, the lesion is defined by its complement-mediated pathogenesis as much as its histological pattern. As a bevy of complement-targeting agents are moving through development and clinical trials, we review the evolution in treatment paradigms for C3G. Here we survey the limited efficacy of noncomplement targeting therapy before focusing on the work being done on targeting various components of the complement cascade in aiming to provide disease-specific therapy.

| S-EPMC10927479 | biostudies-literature

The Human Accelerated Region HACNS1 modifies developmental gene expression in humanized mice

Project description:Understanding how uniquely human genetic changes altered developmental processes is essential to understanding human evolution. We investigated the role of the Human Accelerated Region HACNS1 in human limb evolution by directly interrogating its biological functions in a humanized mouse model. Using genome-wide epigenetic profiling, we found that HACNS1 maintains its human-specific transcriptional enhancer activity compared to its chimpanzee ortholog in the mouse embryonic limb, and that it alters promoter activity of the transcription factor gene Gbx2. Using single-cell transcriptional profiling, we demonstrate that Gbx2 is upregulated in humanized limb bud chondrogenic mesenchyme, providing insight into the developmental processes altered due to human-specific alterations in enhancer activity. Our findings establish that HACNS1 directs changes in the level and distribution of gene expression during development, and illustrate how humanized mouse models provide insight into regulatory pathways altered in human evolution.

2020-12-01 | GSE141471 | GEO

The Human Accelerated Region HACNS1 modifies developmental gene expression in humanized mice

Project description:The Human Accelerated Region HACNS1 modifies developmental gene expression in humanized mice

| PRJNA593575 | ENA

Circulating small RNAs in transplant glomerulopathy

Project description:Transplant glomerulopathy (TG) develops through multiple mechanisms including donor-specific antibodies, T cells and innate immunity. This study investigates the role of circulating small RNAs (sRNAs) in TG

2021-06-30 | GSE156874 | GEO

Update on C3 glomerulopathy.

Project description:C3 glomerulopathy refers to a disease process in which abnormal control of complement activation, degradation or deposition results in predominant C3 fragment deposition within the glomerulus and glomerular damage. Recent studies have improved our understanding of its pathogenesis. The key abnormality is uncontrolled C3b amplification in the circulation and/or along the glomerular basement membrane. Family studies in which disease segregates with structurally abnormal complement factor H-related (CFHR) proteins demonstrate that abnormal CFHR proteins are important in some types of C3 glomerulopathy. This is currently thought to be due to the ability of these proteins to antagonize the major negative regulator of C3 activation, complement factor H (CFH), a process termed 'CFH de-regulation'. Recent clinicopathological cohort studies have led to further refinements in case definition, culminating in a 2013 consensus report, which provides recommendations regarding investigation and treatment. Early clinical experience with complement-targeted therapeutics, notably C5 inhibitors, has also now been published. Here, we summarize the latest developments in C3 glomerulopathy.

| S-EPMC4848753 | biostudies-literature

Circulating small RNAs in transplant glomerulopathy

Project description:Circulating small RNAs in transplant glomerulopathy

| PRJNA659355 | ENA

Paraburkholderia sp. C3 strain:C3

Project description:Paraburkholderia sp. C3 strain:C3 Genome sequencing

| PRJNA684679 | ENA

Pantoea sp. C3 strain:C3

Project description:Pantoea sp. C3 strain:C3 Genome sequencing

| PRJNA1170070 | ENA